<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Qureshi H</submitter><pubmed_abstract>&lt;i>Shigella dysenteriae&lt;/i> has been recognized as the second most prevalent pathogen associated with diarrhea that contains blood, contributing to 12.9% of reported cases, and it is additionally responsible for approximately 200,000 deaths each year. Currently, there is no &lt;i>S. dysenteriae&lt;/i> licensed vaccine. Multidrug resistance in all &lt;i>Shigella&lt;/i> spp. is a growing concern. Current vaccines, such as O-polysaccharide (OPS) conjugates, are in clinical trials but are ineffective in children but protective in adults. Thus, innovative treatments and vaccines are needed to combat antibiotic resistance. In this study, we used immuno-informatics to design a new multiepitope vaccine and identified &lt;i>S. dysenteriae&lt;/i> strain SD197's membrane protein targets using &lt;i>in-silico&lt;/i> methods.</pubmed_abstract><journal>Frontiers in genetics</journal><pagination>1361610</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11143797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Designing a multi-epitope vaccine against &lt;i>Shigella dysenteriae&lt;/i> using immuno-informatics approach.</pubmed_title><pmcid>PMC11143797</pmcid><pubmed_authors>Qureshi H</pubmed_authors><pubmed_authors>Jamal SB</pubmed_authors><pubmed_authors>Basheer A</pubmed_authors><pubmed_authors>Faheem M</pubmed_authors><pubmed_authors>Rai SK</pubmed_authors><pubmed_authors>Arshad MW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Designing a multi-epitope vaccine against &lt;i>Shigella dysenteriae&lt;/i> using immuno-informatics approach.</name><description>&lt;i>Shigella dysenteriae&lt;/i> has been recognized as the second most prevalent pathogen associated with diarrhea that contains blood, contributing to 12.9% of reported cases, and it is additionally responsible for approximately 200,000 deaths each year. Currently, there is no &lt;i>S. dysenteriae&lt;/i> licensed vaccine. Multidrug resistance in all &lt;i>Shigella&lt;/i> spp. is a growing concern. Current vaccines, such as O-polysaccharide (OPS) conjugates, are in clinical trials but are ineffective in children but protective in adults. Thus, innovative treatments and vaccines are needed to combat antibiotic resistance. In this study, we used immuno-informatics to design a new multiepitope vaccine and identified &lt;i>S. dysenteriae&lt;/i> strain SD197's membrane protein targets using &lt;i>in-silico&lt;/i> methods.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-04-25T03:29:01.153Z</modification><creation>2026-04-25T03:22:29.99Z</creation></dates><accession>S-EPMC11143797</accession><cross_references><pubmed>38826807</pubmed><doi>10.3389/fgene.2024.1361610</doi></cross_references></HashMap>